强生医疗旗下Codman Neuro将收购新型血栓清除设备公司Neuravi

4月10日，强生医疗旗下的神经外科与神经血管业务部门Codman Neuro表示将收购爱尔兰医疗器械公司Neuravi以及其神经与血管治疗技术的产品组合，交易金额未披露。

Neuravi公司生产EmboTrap 和EmboTrap II血管再生平台，用于治疗急性缺血性脑卒中。该设备能够通过移除脑部血管中的血栓立即恢复正常血液流动来治疗患者。

快速恢复正常血液流动的治疗对中风患者来说是至关重要的，EmboTrap具有显着优势，例如能够完全清除血栓，避免残余血块逃逸所导致的其他安全性问题，此外该设备能够在血栓清除前就恢复阻塞血管血液流动，有助于患者治疗。

据悉，急性缺血性脑卒中占整个中风事件的87%以上，同时也是中风中造成死亡和残疾的首要原因。据统计，每年欧洲和美国发生急性缺血性脑卒中的患者分别为100万人和70万人。仅在美国，该疾病的预计治疗费用就达到了650亿美元之多。强生Codman Neuro在新闻稿中表示，此次交易展示了公司在为中风患者提供创新治疗产品上强有力的承诺。

  查看下文了解更多内容

Codman Neuro acquires Neuravi

Johnson & Johnson (NYSE:JNJ)business unit Codman Neuro said today it acquired Neuravi andits portfolio of neurovascular therapy technology for an undisclosed amount.

Neuravi produces the EmboTrap and EmboTrap II revascularization platforms designed capture clots and allow blood flow to resume immediately after the clot has been secured in patients who have experienced a stroke.

J&J’s Codman Neuro said that the acquisition, along with its recent Pulsar Vascular buy, demonstrates the company’s “strong commitment to delivering innovative products for stroke therapy,” according to a press release.

“Rapid restoration of flow is of utmost importance when treating stroke patients. The EmboTrap platform was designed to address this critical need and we are excited to combine Neuravi’s expertise in clot research with Codman Neuro’s global resources to accelerate innovation in acute ischemic stroke treatment,” J&J medical devices cardiovascular & specialty solutions group chair Shlomi Nachman said in a prepared statement.

Neuravi’s EmboTrap and EmboTrap II revascularization devices have won CE Mark clearance in the European Union and are currently under investigational use in the US, with a clinical trial in progress to support FDA submission later this year.